The purpose of this paper was to compare the cell-free DNA (cfDNA) yield and the sensitivity and specificity for epidermal growth factor receptor (EGFR) mutations in matched cytology specimens and between cfDNA extracted from the sputum of lung adenocarcinoma specimens using mucolytic solution (MS)-2 compared to MS-1. The effect of disease stage and presence of malignant cells in the sputum on the sensitivity and specificity of the cfDNA assay was also investigated.
Sputum Cell-Free DNA: Valued Surrogate Sample for Detection of EGFR Mutation in Patients with Advanced Lung Adenocarcinoma.
Wang Z, Zhang L, Li L, Li X, Xu Y, Wang M, Liang L, Jiao P, Li Y, He S, Du J, He L, Tang M, Sun M, Yang L, Di J, Zhu G, Shi H, Liu D
Purpose
Conclusion
Extraction of cfDNA from sputum using MS-2 yielded a higher mean concentration of cfDNA and higher genotype concordance with the matched cytology specimen than when extraction was with MS-1. The sensitivity of the cfDNA assay for EGFR mutations in the biopsy was higher in patients with stage IIIB-IV than stage 1-IIIA lung adenocarcinoma. When sputum was classified based on centrifugal sediments, cfDNA from sputum with cells classified as malignant showed higher sensitivity for the detection of EGFR mutations in the biopsy than cfDNA from sputum with cells classified as satisfactory (epithelial cells and macrophage observed but no malignant cells observed) or unsatisfactory (insufficient epithelial cells and macrophages).
Studies (1)
Purpose
The purpose of this study was to compare the cfDNA yield and the sensitivity and specificity for EGFR mutations in matched cytology specimens and between cfDNA extracted from the sputum of lung adenocarcinoma specimens using MS-2 compared to MS-1. The effect of disease stage and presence of malignant cells on the sensitivity and specificity of the cfDNA assay was also investigated. Sputum was collected from 102 lung adenocarcinoma patients (40 stage 1-IIA and 62 stage IIIB-IV) with paired FFPE cytology specimens. Sputum was treated with physiological saline solution (MS-2, all specimens) or CytoLyt solution (MS-1, only 21 lung adenocarcinoma specimens), followed by dithiothreitol. Specimens were vortexed and centrifuged (conditions not specified). cfDNA was extracted from the sputum supernatant using the AmoyDx Circulating DNA Extraction Kit and from the FFPE cytology specimens using the FFPE DNA Extraction Kit and stored at -80°C. EGFR mutation status was analyzed in cfDNA by using the Super-ARMS EGFR Mutation Detection Kit. Slides were prepared from the sputum pellet and classified as unsatisfactory (no epithelial cells or macrophages), satisfactory (epithelial cells and macrophages present but no malignant cells), or malignant (malignant cells observed).
Summary of Findings
Extraction of cfDNA from sputum using MS-2 yielded a higher mean concentration of cfDNA than when MS-1 was used (32.48 ng/µL versus 2.44 ng/µL, P=0.000026). EGFR genotype concordance with the matched cytological specimen was also higher when extraction was with MS-2 compared to MS-1 (81.80% versus 63.60%, P=0.04). cfDNA extracted from sputum using MS-2 had a higher sensitivity for mutations identified in the matched cytological specimen than when extraction was with MS-1 (75% versus 50%, P=0.04) but specificity was comparable (100%, both). Further analysis using the cfDNA extracted from the whole cohort using MS-2 found the assay to have a sensitivity of 46.15% and specificity of 100% for EGFR mutations in the cytological specimen with an overall concordance of cfDNA and cytological specimen for the EGFR genotype of 65.68%. The sensitivity of the cfDNA assay for EGFR mutations in the cytological specimen was higher in patients with stage IIIB-IV than stage 1-IIIA lung adenocarcinoma (65% versus 24%, significance not determined). When sputum was classified based on centrifugal sediments, cfDNA from sputum with cells classified as malignant showed higher sensitivity for the detection of EGFR mutations in the cytological specimen than cfDNA with cells classified as satisfactory (epithelial cells and macrophage observed, but no malignant cells observed) or unsatisfactory (insufficient epithelial cells and macrophages) when analyzed together (92.9% versus 50% and 0%, respectively) or just in patients with Stage I-IIIA lung adenocarcinoma (66.7% versus 23.5% and 0%, respectively) or Stage IIIB-IV lung adenocarcinoma (100% versus 71.4% and 0%, respectively).
Biospecimens
CellLungFluidSputumPreservation Types
FormalinOther PreservativeNone (Fresh)Diagnoses
NormalNeoplasticCarcinomaAsthmaPneumonia/Respiratory InfectionChronic Obstructive Pulmonary Disease (COPD)Other diagnosesPlatforms
DNAReal-time qPCRMorphologyLight microscopyPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition Lung adenocarcinoma patientPatient with non-cancer lung diseasePreaquisition Prognostic factor Stage I-IIIAStage IIIB-IVAnalyte Extraction and Purification Analyte isolation method CytoLyt solution (MS-1)Physiological saline solution (MS-2)